Concerns & Risks -- 7/10
Valuation clearly below peer average (a positive). Multiple near-term, management-controllable
catalysts. China exposure roughly at/just under ~10% on the lower-regulatory-risk private side.
Held from 8-9 by China VBP overhang (delayed but real), Middle East/tariff macro risk, and only
modest top-line growth (guide +3-4%).
Weight: 15%
Forward P/E (FY26E)
~15.7x
vs ~18-20x med-tech peers | Below peer avg
EV/EBITDA (TTM)
~13.0x
vs ~14-20x peers | Discounted
China Exposure
~5-10%
Private-side positioning | Below 10% red-line
FY2026 Guide
+3-4%
rev growth, +100bps non-GAAP OM | Modest but controllable
Valuation vs peers
| Metric | ALGN | Henry Schein | Straumann | Dentsply |
|---|---|---|---|---|
| Forward P/E | ~15.7x | ~22x | — | ~15x |
| EV/EBITDA | ~13.0x | ~13.65x | ~20x | — |
| Read | Below peer avg | In-line | Premium | In-line |
Geographic revenue mix (FY2025)
| Region | Revenue | % of Total |
|---|---|---|
| United States | $1,661M | 41.2% |
| Switzerland (EMEA hub) | $921M | 22.8% |
| Other International (incl. China/APAC) | $1,453M | 36.0% |
China is mid-single-digit to ~10% of total, positioned on private (non-VBP) side.
Catalysts
| Catalyst | Timeline | Detail |
|---|---|---|
| Non-GAAP op margin expansion to ~23.7% (+100bps) | FY2026 | Reaffirmed. Clear, controllable. |
| Comp Zero-AA / DSP Touch-Up | Expanding 2026 | Lower price but margin-accretive, competes vs wires. |
| HFD patient financing | Live now | Live in 4,000+ US offices. Drives conversion in soft consumer environment. |
| DSP launch in APAC | Q2 2026 | Net-new region. |
| Invisalign ART (restorative) + exocad | 2026 pilot | Opens lab channel. |
| $200M buyback | Begun May 2026 | EPS support. |
Regulatory risk
| Risk | Severity | Detail |
|---|---|---|
| China VBP | LOW-MOD | Main overhang; delayed, ALGN under-indexed (private-side). Not in guidance. |
| Middle East | LOW-MOD | Some EMEA patient-traffic impact, bounded. |
| Tariffs | MEDIUM | Guidance assumes no change; open-ended macro risk. |
Bull case
Forward P/E ~15.7x discount to peers. Accelerating volume. Controllable self-help levers
(margin expansion, HFD financing, new SKUs). China surprised positively (record Q1). Massive
untapped TAM (600M+ GP patients vs 22M case starts). Net-cash balance sheet ($1.06B cash).
Bear case
Top-line only +3-4% guide. ASPs guided down 1-2%. Consumer-discretionary nature hostage to soft
US patient traffic. China most competitive market; VBP delayed but real tail risk. Discount
multiple may be a value trap.
Data sourced from Daloopa and public filings. Analysis as of June 2026.